Literature DB >> 32037142

Docetaxel for Early Prostate Cancer: What Have We Learned?

Himisha Beltran1, Michael J Morris2.   

Abstract

Entities:  

Year:  2020        PMID： 32037142     DOI： 10.1016/j.eururo.2020.01.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

Review 1.  Molecular relation between biological stress and carcinogenesis.

Authors:  Katarzyna Rakoczy; Wojciech Szlasa; Natalia Sauer; Jolanta Saczko; Julita Kulbacka
Journal:  Mol Biol Rep       Date:  2022-05-24       Impact factor: 2.742

2.  Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

Authors:  Michael J Morris; Jose Mauricio Mota; Kristine Lacuna; Patrick Hilden; Martin Gleave; Michael A Carducci; Fred Saad; Erica D Cohn; Julie Filipenko; Glenn Heller; Neal Shore; Andrew J Armstrong; Howard I Scher
Journal:  Eur Urol Oncol       Date:  2021-05-18

3.  MicroRNA-mRNA Regulatory Network Mediates Activation of mTOR and VEGF Signaling in African American Prostate Cancer.

Authors:  Himali Gujrati; Siyoung Ha; Azah Mohamed; Bi-Dar Wang
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.